

8th February, 2019

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> |
|---|---|

Scrip Code: 500087

Scrip Code: CIPLA EQ


- (3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

This is further to our letter dated 13th November 2018, we hereby notify that the Company's wholly owned subsidiary i.e. InvaGen Pharmaceuticals Inc., USA has completed the first stage closing of the Avenue Therapeutics Inc. (Avenue), transaction representing an acquisition of 33.3% stake in Avenue's capital stock on fully diluted basis on 8th February 2019.

Thank you,

For Cipla Limited



Rajendra Chopra
Company Secretary

Prepared by: Kamlesh Kulkarni